Considering disease-specific biochemical markers, these can be identified in APS-1, ALD, and SPL1-related FGD, in which screening for 21-hydroxylase antibodies, VLFA, and sphingolipid intermediates should be performed, respectively. Here, SGPL1 is linked to autoimmune polyendocrine syndrome type 1.